Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    

PULMATRIX INC

SummaryChartsNewsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société PULMATRIX INC
01/30PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/30PULMATRIX : Receives Fast Track Designation for Pulmazole for the Treatment of A..
PR
01/16PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/16PULMATRIX : Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR
01/13PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
01/06PULMATRIX : Announces Research Collaboration with Nocion Therapeutics to Explore..
PR
01/02PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
AQ
01/02PULMATRIX : Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Init..
PR
2019PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2019PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2019PULMATRIX, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2019PULMATRIX : appoints Life Sciences Executive Rick Batycky to the Board of Direct..
PR
2019PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2019PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
2019PULMATRIX : Reports Q3 2019 Results
PR
2019PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2019PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2019PULMATRIX : and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating P..
PR
2019PULMATRIX, INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
2019PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2019PULMATRIX : Receives US Patent Covering iSPERSE™ Formulations for Pulmazol..
PR
2019PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2019PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
2019PULMATRIX : Reports Q2 2019 Results
PR
2019PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2019PULMATRIX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
2019PULMATRIX : Activates Sites for Pulmazole Phase 2 Clinical Study
PR
2019PULMATRIX : Change in Directors or Principal Officers, Financial Statements and ..
AQ
2019PULMATRIX, INC. : Shareholder Director Nominations (form 8-K)
AQ
2019PULMATRIX, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2019PULMATRIX : Announces Leadership Change
PR
2019PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2019PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
2019PULMATRIX : Reports Q1 2019 Results
PR
2019PULMATRIX : Cipla Technologies LLC and Pulmatrix enter into Definitive Agreement..
AQ
2019PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
AQ
2019PULMATRIX : and Cipla Technologies LLC enter into Definitive Agreement for the D..
PR
2019PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
AQ
2019PULMATRIX, INC. : Announces Closing of $16.6 Million Upsized Public Offering
PR
2019PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2019PULMATRIX, INC. : Announces Pricing of $14.4 Million Upsized Public Offering
PR
2019PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
AQ
2019PULMATRIX : Enters Into Binding Term Sheet with Cipla Technologies LLC for the D..
PR
2019PULMATRIX : to Participate in Upcoming Investor Conferences
PR
2019PULMATRIX : Regains NASDAQ Compliance
PR
2019PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2019PULMATRIX : Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary D..
PR
2019PULMATRIX : Receives Five Patents Supporting Claims for their Novel Inhaled Narr..
PR
2019PULMATRIX, INC. : Announces $2.5 Million Registered Direct Offering Priced At-th..
PR
2019PULMATRIX : Receives IND Approval for Pulmazole Phase 2 Clinical Study
PR
2019PULMATRIX, INC. : Announces Termination of Planned Offering Pursuant to Registra..
PR
2019PULMATRIX, INC. : Announces 1-for-10 Reverse Stock Split
PR
2019PULMATRIX, INC. : Announces Closing of Public Offering of Common Stock
PR
2019PULMATRIX, INC. : Announces Closing of Public Offering of Common Stock
PR
2019PULMATRIX, INC. : Announces Pricing of Public Offering of Common Stock
PR
2019PULMATRIX, INC. : Announces Proposed Public Offering of Common Stock
PR
2019PULMATRIX, INC. : Announces Pricing of Public Offering of Common Stock
PR
2019PULMATRIX, INC. : Announces Proposed Public Offering of Common Stock
PR
2018PULMATRIX : Announces $3.0 Million Registered Direct Offering
PR
2018PULMATRIX : Reports Q3 2018 Results
PR
2018PULMATRIX : to present pre-clinical data on PUR1800 (RV1162) at the European Res..
PR
2018PULMATRIX : to Present at the 20th Annual Rodman & Renshaw Global Investment Con..
PR
2018PULMATRIX : Reports Q2 2018 Results
PR
2018PULMATRIX : Announces the Formation of the Pulmazole Clinical Advisory Board to ..
PR
2018PULMATRIX : Announces Positive Top-Line Preliminary Results from Part 3 of the 3..
PR
2018PULMATRIX : Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part..
PR
2018PULMATRIX : Announces Approval of Proposals Submitted to Company's Stockholders
PR
2018PULMATRIX : Reports Q1 2018 Results
PR
2018PULMATRIX : Announces Pricing Of $15.2 Million Underwritten Public Offering
PR
2018PULMATRIX : Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary D..
PR
2018PULMATRIX : Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole..
PR
2018PULMATRIX : Will Present Pulmazole Preclinical Data at the 8th Advances Against ..
PR
2018PULMATRIX : Announces Acceptance of a Clinical Trial Application in Europe for P..
PR
2017PULMATRIX : Provides Q3 2017 Highlights and Q3 2017 Updated Financials
PR
2017PULMATRIX : Appoints Dr. James Roach as Chief Medical Officer
PR
1  2Next
Upcoming event on PULMATRIX INC